key: cord-0831100-zh9mvowm
authors: Shoar, Saeed; Hosseini, Fatemeh; Naderan, Mohammad; Mehta, Jawahar L.
title: Meta-analysis of Cardiovascular Events and Related Biomarkers Comparing Survivors vs. Non-survivors in Patients with COVID-19
date: 2020-09-08
journal: Am J Cardiol
DOI: 10.1016/j.amjcard.2020.08.044
sha: 32e49b2566d684ebd7fb9a1ba8d1935f94883e56
doc_id: 831100
cord_uid: zh9mvowm

Since the emergence of the coronavirus disease 19 (COVID-19), a number of studies have reported the presence of cardiovascular diseases in affected patients and linked them with a higher risk of mortality. We conducted an online search in Medline/PubMed to identify original cohorts comparing data between survivors and non-survivors from COVID-19. The presence of cardiovascular events and related biomarkers were compared between the two groups. Data on 1,845 hospitalized patients with COVID-19 were pooled from 12 comparative studies. The overall mortality rate in relation to COVID-19 was 17.6%. Men aged > 50 years old were more likely to die from COVID-19. Significant co-morbidities contributing to mortality were hypertension, diabetes mellitus, smoking, a previous history of cardiovascular disease including chronic heart failure, and cerebrovascular accidents. A significant relationship was observed between mortality and patient presentation with dyspnea, fatigue, tachycardia, and hypoxemia. Cardiovascular disease-related laboratory biomarkers related to mortality were elevated serum level of lactate dehydrogenase, creatine kinase, and cardiac troponin I. Adverse cardiovascular disease-related clinical events preceding death were shock, arrhythmias, and acute myocardial injury. In conclusion, elevated biomarkers in COVID-19 patients with established risk factors can predict mortality from cardiovascular causes.

As the pandemic of coronavirus disease , caused by the severe acute respiratory syndrome novel coronavirus 2 (SARS-CoV-2) is evolving, an increasing number of studies are pointing to the relationship of cardiovascular disease with mortality among hospitalized patients [1] [2] [3] [4] [5] . Most previously published studies on this subject consist of small to large series of patients who had or developed cardiovascular events as a result of infection with SARS-CoV-2. However, few studies have compared the presence of cardiovascular disease risk factors and its manifestations and related laboratory parameters with regard to mortality in patients with COVID-19 infection. We performed a systematic analysis of cardiovascular disease risk factors and manifestations and related laboratory parameters between survivors and nonsurvivors of COVID-19.

A systematic review was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 6 and performed in compliance with the MOOSE (Meta-analyses Of Observational Studies in Epidemiology) Checklist 7 . Two independent researchers performed the literature review, screened the articles, and obtained the full text of the eligible studies.

An electronic search was performed in Medline/PubMed to identify studies with original data on mortality in patients with COVID-19. A combination of the following keywords was used: "COVID-19" or "SARS-COV-2" or "SARS CoV-2" or "2019 novel coronavirus" or "2019-nCOV" and "mortality" or "death" or "died" or "die". Due to a high volume of preprint publication on this topic, we limited our online database search to the Medline/PubMed. The title and abstract of articles were screened for relevancy and the full text of relevant studies were reviewed for eligibility.

Original studies in adult patients with COVID-19 comparing the demographics, clinical characteristics, radiologic findings, or laboratory parameters between survivors and nonsurvivors were eligible for inclusion if available in English language full-text. Furthermore, the articles were included into the quantitative meta-analysis if data on variables of interest were extractable in crude numbers for both the survivor and non-survivor groups. Case report, review articles, modelling studies, and commentaries were excluded. Cochrane Collaboration, 2014) was used to perform meta-analysis of the extracted data in this systematic review. Data on variables of interest was extracted from at least two eligible studies to perform the quantitative analysis. An odds ratio (OR) was calculated as the prevalence of a potential risk factor in the non-survivor group compared to the survivor group. A mean difference (MD) was a weighted difference in the mean of a continuous variable between the two groups. If enough data was available, the laboratory parameters were analyzed both as continuous variables, i.e. their average serum levels, and as categorical variables, i.e. the reported value as elevated or positive. Mantel-Haenszel statistical method was applied using a randomeffects analysis model. Statistical significance was set at p < 0.05. Figure 1 shows the PRISMA flowchart of systematic literature review, article screening, and study selection. Death from COVID-19 occurred in 574 patients, while 1,271 patients survived and were discharged from the hospital ( Table 1 ). The mortality rate ranged from 11.3% 19 to 61.5% 16 A meta-analysis was also performed on available data on four major therapeutic modalities provided to COVID-19 patients. These include antiviral treatment, antibiotics, corticosteroid administration, and mechanical ventilation. Of these, corticosteroids (OR = 3.3, p =0.001) and mechanical ventilation (OR = 9.07, p = 0.02) were used more commonly in nonsurvivors than in survivors (Figure 3 ).

Our analysis of comparative studies in hospitalized patients with COVID-19 shows that patients who died had a significant involvement of cardiovascular system. Non-survivors had preponderance of cardiovascular disease risk factors-male gender, history of dyslipidemia, smoking, hypertension, and diabetes. They also had a significant past history of pre-existing cardiovascular disease, including chronic heart failure and cerebrovascular accidents. At presentation, they had high prevalence of hypoxemia, high heart rate, dyspnea, and fatigue suggesting cardiovascular system instability. While in the hospital, the non-survives had a significant increase in laboratory biomarkers such as cardiac troponin I, LDH and CK, suggesting new cardiac injury or worsening of pre-existing heart disease. Not surprisingly, the non-survivors had clinical evidence of cardiovascular system instability as manifested by the presence of shock, cardiac arrhythmias, and acute respiratory distress (eFigure1).

In a large series of hospitalized patients with COVID-19 in New York City, Lala et al 5 showed that elevated troponin I level was significantly associated with coronary artery diseases, atrial fibrillation, and heart failure. These authors suggested a 3-fold increase in the mortality rate with troponin-I elevation 3-times above the upper reference limit.

In an attempt to develop a risk prediction model, Liang et al 20 used the retrospective data of the National Health Commission of China to identify independent predictors of mortality in COVID-19 patients. The validated results showed that an abnormality on chest radiography, age, hemoptysis, dyspnea, unconsciousness, number of comorbidities, a history of cancer, neutrophilto-lymphocyte ratio, lactate dehydrogenase, and direct bilirubin remained independent predictors of death.

Chen et al. compared cardiovascular system variables in a small number of severely sick (39 cases) and critically sick (15 cases) COVID-19 patients, 4 and found that diabetes, significant leukocytosis, inflammatory elements (interleukin-6, C-reactive protein, erythrocyte sedimentation rate, D-dimer, and procalcitonin), markers of myocardial injury (CK-MB, troponin-I, myoglobin, and pro-BNP), hypotension and tachycardia at admission, atrioventricular block, pericardial effusion, and right heart block were more prevalent in critically-ill patients.

In our study, we focused on cardiovascular disease risk factors and its manifestations, and related laboratory biomarkers were powerful predictors of death in COVID-19 patients. Our analysis of several large and small studies confirmed the hypothesis that cardiovascular system instability predicts survivorship in COVID-19 patients. Unfortunately, the included studies did not provide sufficient data on the type of cardiac arrhythmia. Also, due to the limited number of events for each subgroup analysis, some variables did not reach a statistical significance of which an acute heart failure is a major one. Although studying the efficacy of various therapeutic modalities was beyond the scope of our meta-analysis, non-survivors had a tendency to receive more aggressive treatment such as mechanical ventilation and corticosteroid administration.

However, none of these therapeutic modalities seemed to improve the survival in patients with COVID-19.

In conclusion, this meta-analysis of comparative studies highlights the pivotal role of cardiovascular system instability in predicting mortality in patients with COVID-19. A careful history of cardiovascular disease and its risk factors, attention to signs and symptoms at presentation and during hospitalization, and related laboratory parameters should alert the clinicians towards the high-risk patient.

All authors have no conflict of interests to disclose.

This study did not receive any grant or financial support in any forms. Table 1 . Characteristics of studies included in this review. Table 2 . Factors associated with mortality from COVID-19 in the meta-analysis of comparative studies. All studies were published in 2020. N/A: Not available. The meta-analysis estimated a mean difference and 95% confidence interval for the continuous variables and an odds ratio and 95% confidence interval for the adverse event incidents. Mantel-Haenszel statistical method using a random-effects model was used for all the analysis.

Age > 50 years

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Cardiac troponin i is an independent predictor for mortality in hospitalized patients with coronavirus disease

Electrocardiographic features of patients with COVID-19 pneumonia

Cardiovascular manifestations in severe and critical patients with COVID-19

Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection

Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group

Clinical features and short-term outcomes of 102 patients with Coronavirus disease

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study

Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Clinical and transmission characteristics of Covid-19 -a retrospective study of 25 cases from a single thoracic surgery department

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study

China Medical Treatment Expert Group for C. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19

Variables are presented as odds ratio, unless mentioned otherwise, i.e. mean difference